Mitsubishi Chemical's clinical study demonstrates effectiveness of probiotic on intestinal environment
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Subscribe To Our Newsletter & Stay Updated